Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2022 07:00 ET | Source: Ocuphire Pharma

Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

FARMINGTON HILLS, Mich., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
September 12, 2022 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA

FARMINGTON HILLS, Mich., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
September 08, 2022 08:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

Top-line Results are Expected in 4Q 2022 Interim Masked Safety Results Seen Demonstrate Favorable Safety and Tolerability Profile, Consistent with 11 Prior Trials of APX3330 Oral APX3330 has the...
September 06, 2022 09:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference

FARMINGTON HILLS, Mich., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
August 12, 2022 07:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update

Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023 Approval Positive...
August 08, 2022 07:00 ET | Source: Ocuphire Pharma

Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August

Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022 H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022, including a Fireside Panel with OCUP “Front of...
August 03, 2022 08:00 ET | Source: Ocuphire Pharma

Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance

Issuance Extends Nyxol's U.S. Patent Protection from 2034 into 2039 for RM Indication Growing Patent Estate Eligible for FDA Orange Book Listing On Track to File NDA for Nyxol in First Indication...
July 07, 2022 08:00 ET | Source: Ocuphire Pharma

Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July

Mina Sooch CEO to Present at Ophthalmic Innovation Panel at the 11th Annual AECOS Summer Symposium and OIS Retina Innovation Summit ASRS Late-Breaking Paper Highlighting Data from Two Phase 3...
June 29, 2022 09:00 ET | Source: Ocuphire Pharma

Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication

Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and Extends Expiry Thru 2038 Peer-Reviewed Publication Highlights the Critical Role of Inflammation...
June 08, 2022 08:00 ET | Source: Ocuphire Pharma

Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting

Of 103 Diabetic Subjects Enrolled in the 24-week ZETA-1 Phase 2b Trial, 70% Have Completed 12 or More Weeks Topline Results with First-in-Class Non-Invasive Retinal Candidate APX3330 Expected in...